Confirmed germline pathogenic / likely-pathogenic variant in NF1 OR fulfillment of NIH/Be...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | RF-NF1-CONFIRMED-CARRIER |
|---|---|
| Type | Red flag |
| Status | reviewed 2026-05-19 | pending_clinical_signoff |
| Diseases | DIS-BREAST DIS-GLIOMA-LOW-GRADE DIS-SOFT-TISSUE-SARCOMA |
| Sources | SRC-NCCN-BREAST-2025 SRC-NCCN-GENETIC-FAMILIAL-BREAST-OVARIAN-2025 |
Red Flag Origin
| Definition | Confirmed germline pathogenic / likely-pathogenic variant in NF1 OR fulfillment of NIH/Bethesda clinical diagnostic criteria for neurofibromatosis type 1 (≥2 of: ≥6 café-au-lait macules >5 mm pre-pubertal or >15 mm post-pubertal, ≥2 neurofibromas or 1 plexiform neurofibroma, axillary/inguinal freckling, optic pathway glioma, ≥2 Lisch nodules, distinctive osseous lesion, FDR with NF1). NF1 is an autosomal-dominant tumor-predisposition syndrome with ~1 in 3000 prevalence — most common single-gene cancer predisposition syndrome. Cancer spectrum: optic pathway glioma (children, ~15-20%), other CNS gliomas (low- and high-grade across the lifespan, ~5-15% adult prevalence), malignant peripheral nerve sheath tumor (MPNST, ~10-15% lifetime, malignant transformation of plexiform neurofibroma — major life-limiting complication), breast cancer in women (lifetime ~18% by age 50, ~50% by age 70 — co... |
|---|---|
| Clinical direction | investigate |
| Category | other |
Trigger Logic
{
"any_of": [
{
"finding": "germline_nf1_pathogenic_variant_confirmed",
"value": true
},
{
"finding": "nih_nf1_clinical_diagnostic_criteria_met",
"value": true
},
{
"finding": "germline_nf1_likely_pathogenic_variant",
"value": true
}
],
"type": "lab_value"
}
Notes
Prevention-persona RedFlag for NF1 confirmed-carrier / clinical- diagnostic-criteria-met cohort. Multi-organ surveillance: pediatric ophthalmology q6-12mo to age 8 (optic glioma); whole-body MRI for MPNST surveillance + symptom-driven biopsy of growing/painful/ neurologically-symptomatic plexiform neurofibromas; women: annual mammography from age 30, MRI from age 30-50. STUB pending two-Co- Lead signoff per CHARTER §6.1 dev-mode.
Used By
Indications
IND-NF1-CARRIER-PREVENTION-OBSERVATION- IND-NF1-CARRIER-PREVENTION-OBSERVATIONIND-NF1-CARRIER-PREVENTION-SURVEILLANCE- IND-NF1-CARRIER-PREVENTION-SURVEILLANCEIND-NF1-SUSPICION-PREVENTION-TESTING- IND-NF1-SUSPICION-PREVENTION-TESTING
Red flag
RF-NF1-FAMILY-HISTORY-SUSPICION- Family pedigree pattern suggestive of germline NF1 carrier state in an asymptomatic indiv...